Huntingtons Disease
BMJ 341:34-40, Novak,M.J. &Tabrizi,S.J., 2010
Longitudinal Change in Basal Ganglia Volume in Patients with Huntington's Disease
Neurol 48:394-399, Aylward,E.H.,et al, 1997
Reduced Basal Ganglia Volume Associated with the Gene for Huntington's Disease in Asymptomatic at-Risk Persons
Neurol 44:823-828, Aylward,E.H.,et al, 1994
Clinical-Pathologic Correlation in Huntington's Disease:A Neuropsychological and Computed Tomography Study
Neurol 39:796-801, Bamford,K.A.,et al, 1989
Bicaudate Index in Computerized Tomography of Huntington Disease & Cerebral atrophy
Neurol 28:1196-1200, Barr,A.N.,et al, 1978
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996
Molecular Genetics in Neurology
Ann Neurol 34:757-773, Martin,J.B., 1993
Serial Changes of Cerebral Glucose Metab & Caudate Size in Persons at Risk for Huntington's Dis
Arch Neurol 49:1161-1167, Grafton,S.T.,et al, 1992
The Role of Glutamate in Neurotransmission & in Neurologic Disease
Arch Neurol 43:1058-1063, Greenamyre,J.T., 1986
Positron Computed Tomography for Studies of Myocardial & Cerebral Function
Ann Int Med 98:339-359, Phelps,M.E.,et al, 1983
Clinical Neuropathological Conference
(Ed) , Dis Ner Sys 34:124, 1973, Pick's Disease., Aronson,S.&Aronson,B., 1973
Huntington Disease: Clinical Features and Diagnosis
UptoDate Dec 2017, Oksana Suchowersky, 2017
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
CAG Repeat Number Governs the Development Rate of Pathology in Huntington's Disease
Ann Neurol 41:689-692, Penney,J.B.,et al, 1997
Juvenile Huntington Disease:CT and MR Features
AJNR 16:1405-1412, Ho,V.B.,et al, 1995
Trinucleotide Repeat Length and Rate of Progression of Huntington's Disease
Ann Neurol 36:630-635, Illarioshkin,S.N.,et al, 1994
Trinucleotide Repeat Expansion in Neurological Disease
Ann Neurol 36:814-822, LaSpada,A.R.,et al, 1994
Cortical Myoclonus in Huntington's Disease
Movement Disorders 9:633-641, Thompson,P.D.,et al, 1994
Normal Caudate Glucose Metabolism in Persons at Risk for Huntington's Disease
Arch Neurol 44:254-257, Young,A.B.,et al, 1987
Reduced Cerebral Glucose Metabolism in Asymptomatic Subjects at Risk for Huntington's Disease
NEJM 316:357-362, Mazziotta,J.C.,et al, 1987
The Combined Use of Positron Emission Tomography & DNA Polymorphisms for Preclinical Detection of Huntington's Disease
Neurol 37:1441-1447, Hayden,M.R.,et al, 1987
Positron Emission Tomography in the Early Diagnosis of Huntington's Disease
Neurol 36:888-894, Hayden,M.R.,et al, 1986
Neuropeptides in Neurological Disease
Ann Neurol 20:547-565, Beal,M.F.&Martin,J.B., 1986
PET Scan Investigations of Huntington's Disease:Cerebral Metabolic Corr. of Neuro & Funct Decline
Ann Neurol 20:296-303, Young,A.B.,et al, 1986
Evoked Potentials in Huntington's Disease
Arch Neurol 41:379-382, Ehle,A.L.,et al, 1984
Neurotransmitters & CNS Disease, Basal Ganglia Disease
Lancet 2:1141-1147, Marsden,C.D., 1982
Levels of y-Aminobutyric Acid in Cerebrospinal Fluid in Various Neurologic Disorders
Arch Neurol 37:352-355, Manyam,N.V.B.,et al, 1980
The Visually Evoked Potential in Huntington disease
Neurol 28:95, Ellenberger,C.,et al, 1978
Identification of GABA in Human CSF by Gas Liquid Chromatography & Mass Spectrometry
NEJM 296:692, Huizinga,J.D.,et al, 1977
Clinical Diagnosis of the Dyskinesias
Med Clin of North Am 56:1321, Duvoisin,R., 1972
Diseases of the Extrapyramidal System
Disease-a-month-Jan 1970., Klawans,H.,et al, 1970
Diseases of the Basal Ganglia-Their Relation to Disorders of Movement
Lancet 1099, 1960, Nov., Denny-Brown,D., 1960